IDT acquires GeneWorks oligo business

IDT acquires GeneWorks oligo business

Integrated DNA Technologies acquires oligo manufacturing business of GeneWorks (Australia).

Integrated DNA Technologies acquires oligo manufacturing business of GeneWorks (Australia).

IDT expands its capacity for direct sales of genomic products in Asia-Pacific region

SKOKIE, IL (February 08, 2017) Integrated DNA Technologies (IDT), through its Singapore subsidiary, today completed the acquisition of the oligonucleotide manufacturing business of GeneWorks Pty Ltd. (GeneWorks) in Australia. This acquisition sees IDT expand its reach in the Asia-Pacific region, following its recent establishment of sales offices in Japan and Korea.

As the global leader in custom nucleic acid synthesis, IDT offers GeneWorks customers a broad range of manufacturing options for oligos as well as other high quality products for genomics research. GeneWorks will continue offering molecular and cell biology products and associated services, and both companies are committed to a seamless transition of the business for customers.

Dr Joseph A Walder, IDT founder and CEO, commented, “With this acquisition, we are furthering our goal of making our world-class products and services more easily accessible to scientists around the world. We look forward to availing GeneWorks’ customers of our unrivalled manufacturing capabilities, design expertise, and fast turnaround times.”

Peter Guilhaus, Managing Director of GeneWorks, agrees, “With IDT, our customers will continue to receive reliable oligo manufacturing and excellent customer service. We are pleased to begin the transitioning process and are confident our customers will find working with IDT to be efficient, easy, and cost-effective.”

Editors’ notes

About IDT 
Integrated DNA Technologies (IDT) is the world leader in delivering custom nucleic acid products for the life sciences market in the areas of academic research, medical diagnostics, biotechnology, agriculture, and pharmaceutical development. The company's primary business is the production of custom oligonucleotides for molecular biology applications. IDT has developed proprietary technologies for genomics applications such as next generation sequencing, CRISPR genome editing, qPCR, and RNA interference. Through its GMP services, IDT manufactures products used in diagnostic tests for cancer and most inherited and infectious diseases. For more information, visit www.idtdna.com.

BACK